Stockreport

Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
PDF -- Top-line Results Expected Fourth Quarter of 2020 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceu [Read more]